#ACR23 Abstr#0840 Could combined JAK1/Tyk2 fare better than Tofacitinib in D2T #RA? Phase 2 RCT showed impressive result
Tweet Content
#ACR23 Abstr#0840 Could combined JAK1/Tyk2 fare better than Tofacitinib in D2T #RA? Phase 2 RCT showed impressive results; > %50 pts in the higher doses TLL-018 arms achieved ACR50 vs TOF (42%). TOF non-responders at WK12 who switched to TLL-018 improved too @RheumNow #ACRBest https://t.co/Yw6Pvb2PH8
Show on Archive Page
On
Display in Search Results
On
PDQ
Off